دورية أكاديمية
Analysis of Adherence to anti-PCSK9 Antibody Therapy among Patients from Italy.
| العنوان: | Analysis of Adherence to anti-PCSK9 Antibody Therapy among Patients from Italy. |
|---|---|
| المؤلفون: | Mongiello P; Specializzando in Farmacia Ospedaliera presso l'Università degli Studi di Bari e tirocinante presso la Struttura Complessa di Farmacia Territoriale dell'Azienda Sanitaria Locale di Foggia, 71121 Foggia, Italy., Petti R; Dirigente Farmacista presso la Struttura Complessa di Farmacia Territoriale dell'Azienda Sanitaria Locale di Foggia, 71121 Foggia, Italy., Ciaccia A; Dirigente Farmacista presso la Struttura Complessa di Farmacia Territoriale dell'Azienda Sanitaria Locale di Foggia, 71121 Foggia, Italy., Grazia Morgese M; Professoressa presso il Dipartimento di Medicina Clinica e Sperimentale dell'Università degli Studi di Foggia, 71122 Foggia, Italy., Lombardi R; Direttore della Struttura Complessa di Farmacia Territoriale dell'Azienda Sanitaria Locale di Foggia, 71121 Foggia, Italy. |
| المصدر: | Cardiovascular & hematological disorders drug targets [Cardiovasc Hematol Disord Drug Targets] 2023; Vol. 23 (2), pp. 111-121. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Bentham Science Publishers Country of Publication: United Arab Emirates NLM ID: 101269160 Publication Model: Print Cited Medium: Internet ISSN: 2212-4063 (Electronic) Linking ISSN: 1871529X NLM ISO Abbreviation: Cardiovasc Hematol Disord Drug Targets Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Sharjah, U.A.E. ; San Francisco, CA : Bentham Science Publishers, [2006]- |
| مواضيع طبية MeSH: | Proprotein Convertase 9* , Hypercholesterolemia*/chemically induced , Hypercholesterolemia*/drug therapy, Male ; Young Adult ; Humans ; Female ; Adult ; Middle Aged ; PCSK9 Inhibitors ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal/pharmacology |
| مستخلص: | Introduction: Hypercholesterolemia is one of the main risk factors associated with atherosclerotic cardiovascular disease and coronary heart disease. Statins are the standard cholesterollowering treatment; however, they have shown, in clinical practice, a reduced adherence to therapy (<50%) and a modest achievement of the expected outcomes for treatment. This condition prompt scientific research to develop drugs with different mechanisms of action. In this regard, excellent results have been achieved with therapeutic use of monoclonal antibodies against PCSK9, enzyme involved in recycling of Low density lipoprotein receptors (LDLR) on the hepatocytes surface. Indeed, the reduction in receptor density caused by PCSK9 is associated with increased serum LDL levels. Materials and Methods: After the data extraction of all Local Health Authority (ASL) of Foggia patients (302) who received, in 2021, at least one administration of Alirocumab or Evolocumab, the therapeutic adherence was calculated, for each individual patient, by indirect method (calculation of the Medication Possession Ratio - MPR). According to scientific literature, patients were classified into: adherents (MPR>80%), average adherents (MPR between 40% and 80%) and non-adherents (MPR<40%). Patients were then stratified by gender and age groups (0-18, 19-49, 50-64, >65). Results: The results show that, for both drugs (Alirocumab and Evolocumab), women are more adherent than men and the group of young adults (19-49 years old) is the one with the lowest adherence to therapy, 69% for Alirocumab and 56% for Evolocumab. Conclusion: According to Italian Drug Agency (AIFA), poor therapeutic adherence is the main cause of ineffectiveness of drug therapies, and it is associated with increased hospitalizations, morbidity and mortality. Data obtained from this study allow to detect the categories of patients who need specific programs about the correct use of drugs, in order to increase therapeutic adherence and facilitate the achievement of the expected outcomes for treatment. (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.) |
| فهرسة مساهمة: | Keywords: PCSK9; alirocumab; cardiovascular diseases; evolocumab; hypercholesterolemia; therapeutic adherence. |
| المشرفين على المادة: | EC 3.4.21.- (PCSK9 protein, human) EC 3.4.21.- (Proprotein Convertase 9) 0 (PCSK9 Inhibitors) 0 (Antibodies, Monoclonal) |
| تواريخ الأحداث: | Date Created: 20230811 Date Completed: 20231216 Latest Revision: 20240320 |
| رمز التحديث: | 20240320 |
| DOI: | 10.2174/1871529X23666230810094738 |
| PMID: | 37565557 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2212-4063 |
|---|---|
| DOI: | 10.2174/1871529X23666230810094738 |